Literature DB >> 22986764

Measurement properties of outcome measures for vitiligo. A systematic review.

Charlotte Vrijman1, May W Linthorst Homan, Jacqueline Limpens, Wietze van der Veen, Albert Wolkerstorfer, Caroline B Terwee, Phyllis I Spuls.   

Abstract

OBJECTIVE To summarize and critically appraise the evidence on the measurement properties of clinician-, patient-, and observer-reported outcomes, measuring any construct of interest in patients with all types of vitiligo. DATA SOURCES Electronic databases including PubMed (1948 to July 2011), OVID EMBASE (1980 to July 2011), and CINAHL (EBSCOhost) (1982 to July 2011) were searched. STUDY SELECTION Two authors independently screened all records for eligibility. For inclusion, the study population had to include patients with vitiligo, for which outcome measures were developed or evaluated on their measurement properties. The initial search retrieved 1249 records, of which 14 articles met the inclusion criteria. DATA EXTRACTION Characteristics of the included instruments, study population, and results of the measurement properties were extracted. The Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) 4-point checklist, combined with quality criteria for measurement properties, was used to calculate the overall level of evidence per measurement property of each instrument. Independent extraction and assessment was performed by 2 authors. DATA SYNTHESIS Eleven different measurement instruments were identified. Strong evidence was found for a positive internal consistency of the Dermatology Life Quality Index. For other instruments, the evidence of measurement properties was limited or unknown. CONCLUSIONS Recommendations on the use of specific outcome measures for vitiligo should be formulated with caution because current evidence is insufficient owing to a low number of studies with poor methodological quality and unclear clinical relevance. To recommend outcome measures for vitiligo, further research on measurement properties of clinical relevant outcome measures for vitiligo according to COSMIN quality criteria is needed.

Entities:  

Mesh:

Year:  2012        PMID: 22986764     DOI: 10.1001/archdermatol.2012.3065

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

1.  2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures.

Authors:  Bryant R England; Benedict K Tiong; Martin J Bergman; Jeffrey R Curtis; Salahuddin Kazi; Ted R Mikuls; James R O'Dell; Veena K Ranganath; Alex Limanni; Lisa G Suter; Kaleb Michaud
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-11-11       Impact factor: 4.794

Review 2.  A critical analysis of test-retest reliability in instrument validation studies of cancer patients under palliative care: a systematic review.

Authors:  Carlos Eduardo Paiva; Eliane Marçon Barroso; Estela Cristina Carneseca; Cristiano de Pádua Souza; Felipe Thomé Dos Santos; Rossana Verónica Mendoza López; Sakamoto Bianca Ribeiro Paiva
Journal:  BMC Med Res Methodol       Date:  2014-01-21       Impact factor: 4.615

3.  Psychometric Properties of Language Assessments for Children Aged 4-12 Years: A Systematic Review.

Authors:  Deborah Denman; Renée Speyer; Natalie Munro; Wendy M Pearce; Yu-Wei Chen; Reinie Cordier
Journal:  Front Psychol       Date:  2017-09-07

4.  The long road to valid outcomes in vitiligo.

Authors:  A Wolkerstorfer
Journal:  Br J Dermatol       Date:  2019-03       Impact factor: 9.302

5.  Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practice.

Authors:  Nanja van Geel; Iltefat H Hamzavi; Amit G Pandya; Albert Wolkerstorfer; Julien Seneschal; Amit Garg; Phyllis Spuls; Caroline B Terwee; Sue Mallett; Reinhart Speeckaert; Jean Marie Meurant; Viktoria Eleftheriadou; Khaled Ezzedine
Journal:  Trials       Date:  2022-07-23       Impact factor: 2.728

6.  Measurement of disease severity in cutaneous autoimmune diseases.

Authors:  Cynthia Anyanwu; Jamie Langenhan; Victoria P Werth
Journal:  F1000Prime Rep       Date:  2013-06-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.